Article

Genomics pioneer Venter to be ARVO keynoter

J. Craig Venter, PhD, founder and chief executive officer of Synthetic Genomics Inc., will be the keynote speaker at the annual meeting of the Association for Research in Vision and Ophthalmology.

Rockville, MD-J. Craig Venter, PhD, founder and chief executive officer of Synthetic Genomics Inc., will be the keynote speaker at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

His presentation, which will take place at the opening session of ARVO 2012 on May 6, is entitled “From Reading to Writing the Genetic Code.”

Dr. Venter is regarded as one of the 21st century’s leading scientists. His contributions to genomic research include publication of the first-draft human genome in 2001, the first complete diploid human genome in 2007, and the creation of the first self-replicating bacterial cell constructed entirely with synthetic DNA.

He is founder, chairman, and president of the J. Craig Venter Institute, a nonprofit organization with approximately 300 scientists and staff working on human, microbial, plant, synthetic, and environmental genomic research, as well as the exploration of social and ethical issues in genomics.

Synthetic Genomics is a privately held company developing and applying genomic-driven commercial solutions to markets, including biofuels, biochemicals, and new bio-based food products.

Some 12,000 researchers from 80 countries are expected to attend the 5-day ARVO annual meeting. This year’s theme is “Translational Research: Seeing the Possibilities.” The meeting will feature more than 6,000 pieces of research, which are presented as posters, papers, lectures, symposia, and workshops. Program details and registration information are available at www.arvo.org/am.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.